Status:
COMPLETED
Microbial Resistance of Rifaximin in Hepatic Encephalopathy
Lead Sponsor:
National Hepatology & Tropical Medicine Research Institute
Conditions:
Hepatic Encephalopathy
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Aims and Objectives: To determine the safety and efficacy of rifaximin plus lactulose as secondary prophylaxis of HE compared to lactulose alone. To evaluate the effect of long-term administration of ...
Detailed Description
Methodology Inclusion and exclusion criteria Fully conscious patients were enrolled from the National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt between January 2015 an...
Eligibility Criteria
Inclusion
- \- The inclusion criteria
- cirrhosis due to HCV infection
- age 18 to 75 years,
- experiencing at least one episode of OHE,
- MELD score ≤ 25
Exclusion
- Patients with neurological or communication problems,
- hepatocellular carcinoma
- diabetes mellitus
- active infection
- serum creatinine \> 2 mg/dl, Hg \< 8 g/dL, serum Na \< 125 mmol/L or serum K \< 2.5 mmol/L .
- Patients with previous intake of rifaximin as prophylaxis or any antibiotic within the last month
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04736836
Start Date
January 1 2015
End Date
June 1 2019
Last Update
February 3 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.